Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322791 | 0.98 | LMNA (0.58) | LMNANPSR1EPHX1HPGDKMT2A | |
| SCHEMBL2018813 | 0.89 | — | — | |
| SCHEMBL931108 | 0.83 | NPSR1 (0.62) | LMNANPSR1EPHX1HPGDKMT2A | |
| SCHEMBL15713113 | 0.83 | NPSR1 (0.62) | LMNANPSR1EPHX1HPGDKMT2A | |
| SCHEMBL19669665 | 0.83 | NPSR1 (0.62) | LMNANPSR1EPHX1HPGDKMT2A | |
| SCHEMBL931220 | 0.83 | NPSR1 (0.62) | LMNANPSR1EPHX1HPGDKMT2A | |
| SCHEMBL18010859 | 0.83 | NPSR1 (0.62) | LMNANPSR1EPHX1HPGDKMT2A | |
| SCHEMBL5103623 | 0.81 | LMNA (0.63) | LMNANPSR1EPHX1HPGDKMT2A | |
| SCHEMBL22731140 | 0.81 | LMNA (0.63) | LMNANPSR1EPHX1HPGDKMT2A | |
| SCHEMBL11592487 | 0.81 | NPSR1 (0.60) | LMNANPSR1EPHX1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854637-A | Three tadalafil synthesis process byproducts and preparation method thereof | 南京华威医药科技集团有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-11339128-B2 | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers | FIRMENICH INCORPORATED (US) | 2022-05-24 | — | — | US | disclosed |
| EP-2840080-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | Fujifilm Corporation (JP) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013157540-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | 富士フイルム株式会社 (JP) | 2013-10-24 | — | — | WO | disclosed |
| US-20130041178-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE N-METHYLAMINO ACIDS AND OPTICALLY ACTIVE N-METHYLAMINO ACID AMIDES | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2013-02-14 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339128-B2 | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers | TAS2R5, TAS2R4, TAS2R30 | LMNA 4646/4885NPSR1 1780/4885EPHX1 3634/4885 |
| US-20130041178-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE N-METHYLAMINO ACIDS AND OPTICALLY ACTIVE N-METHYLAMINO ACID AMIDES | NAAA, METTL3, AMD1 | LMNA 830/4885NPSR1 946/4885EPHX1 2290/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | LMNA 4087/4885NPSR1 1147/4885EPHX1 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.